OBJECTIVE: To investigate the metabolic effects of dietary fructose and sucrose in type II diabetic patients. RESEARCH DESIGN AND METHODS: Sixteen well-controlled type II diabetic subjects were fed three isocaloric diets for 28 days each. The three diets provided 50-55, 15, and 30-35% of total energy from carbohydrate, protein, and fat, respectively. In one diet, 20% of total calories were derived from fructose; in another, 19% of total calories were derived from sucrose; and in the control diet, only 5% of daily calories were derived from sugars, all other carbohydrates being supplied as polysaccharides. RESULTS: No significant differences were observed between either the fructose or the sucrose diet and the control polysaccharide diet in any of the measures of glycemic control, serum lipid levels, or insulin and C-peptide secretion. CONCLUSIONS: Our data suggest that in the short and middle terms, high fructose and sucrose diets do not adversely affect glycemia, lipemia, or insulin and C-peptide secretion in well-controlled type II diabetic subjects.
OBJECTIVE: To investigate the metabolic effects of dietary fructose and sucrose in type II diabeticpatients. RESEARCH DESIGN AND METHODS: Sixteen well-controlled type II diabetic subjects were fed three isocaloric diets for 28 days each. The three diets provided 50-55, 15, and 30-35% of total energy from carbohydrate, protein, and fat, respectively. In one diet, 20% of total calories were derived from fructose; in another, 19% of total calories were derived from sucrose; and in the control diet, only 5% of daily calories were derived from sugars, all other carbohydrates being supplied as polysaccharides. RESULTS: No significant differences were observed between either the fructose or the sucrose diet and the control polysaccharide diet in any of the measures of glycemic control, serum lipid levels, or insulin and C-peptide secretion. CONCLUSIONS: Our data suggest that in the short and middle terms, high fructose and sucrose diets do not adversely affect glycemia, lipemia, or insulin and C-peptide secretion in well-controlled type II diabetic subjects.
Authors: Vanessa Ha; Viranda H Jayalath; Adrian I Cozma; Arash Mirrahimi; Russell J de Souza; John L Sievenpiper Journal: Curr Hypertens Rep Date: 2013-08 Impact factor: 5.369
Authors: Huicui Meng; Nirupa R Matthan; Susan K Fried; Silvia Berciano; Maura E Walker; Jean M Galluccio; Alice H Lichtenstein Journal: J Clin Endocrinol Metab Date: 2018-09-01 Impact factor: 5.958
Authors: John L Sievenpiper; Amanda J Carleton; Sheena Chatha; Henry Y Jiang; Russell J de Souza; Joseph Beyene; Cyril W C Kendall; David J A Jenkins Journal: Diabetes Care Date: 2009-07-10 Impact factor: 17.152
Authors: Adrian I Cozma; John L Sievenpiper; Russell J de Souza; Laura Chiavaroli; Vanessa Ha; D David Wang; Arash Mirrahimi; Matt E Yu; Amanda J Carleton; Marco Di Buono; Alexandra L Jenkins; Lawrence A Leiter; Thomas M S Wolever; Joseph Beyene; Cyril W C Kendall; David J A Jenkins Journal: Diabetes Care Date: 2012-07 Impact factor: 19.112